Fireside chat scheduled for Monday, September 14, 2026, at 12:00pm ET NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the H.C.

Fireside chat scheduled for Wednesday, September 9, 2026, at 11:30am ET NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Cantor Global Healthcare

Second quarter 2026 total global revenue of approximately $240 million, including BRIUMVI U.S. net product revenue of approximately $228 million Raises full year 2026 total global revenue target to approximately $950 million and raises full year 2026 BRIUMVI U.S.

Conference Call to be Held Monday, August 3, 2026, at 8:30 am ET NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, August 3, 2026, at 8:30 AM ET to discuss results for the second quarter 2026 and to provide

Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60 patients with treatment-resistant schizophrenia based on emerging evidence linking immune dysfunction to disease in a subset of patients NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc.

82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMVI in patients with MG (n=11) Potential registration-directed Phase 2 trial utilizes novel sequential treatment approach designed to combine rapid symptom

Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 or early 2027  Novel Investigational high concentration subcutaneous formulation of BRIUMVI was

Fireside chat scheduled for Tuesday, June 9, 2026, at 2:00 PM ET NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Goldman Sachs 47 th Annual Healthcare

Treatment with BRIUMVI reduced annualized relapse rate by 56.7% vs. teriflunomide in treatment-naïve patients BRIUMVI demonstrated significant improvements across disability, MRI outcomes, and no evidence of disease activity (NEDA-3) in treatment naïve patients supporting early use of high-efficacy

Fireside chat scheduled for Wednesday, June 3, 2026, at 11:40 AM ET NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Jefferies Global Healthcare